News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Lack of effective treatments for blood cancer patients

Lack of access to effective treatments is forcing blood cancer patients to take desperate measures

12 April 2018

Lack of funded access to life-extending treatments for multiple myeloma is causing some New Zealand patients to take desperate measures, including importing cheap, potentially less effective ‘knock-offs’ of the drug Lenalidomide from India, and in some cases even moving to Australia where another new myeloma treatment (Daratumumab) which is not funded here is available on a compassionate access programme.

Haematologist and chief executive of Myeloma New Zealand Charitable Trust Dr Ken Romeril says very few patients can afford the $100,000.00 it costs per year to receive Daratumumab, which has shown significant gains in survival for myeloma patients.

“It is not illegal to import generic drugs from India, but there are serious questions around the efficacy of some of these generic drugs.

“Getting onto drug trials in New Zealand has been another option for patients seeking access to novel agents, but often the trials are only open for a short time.

“A further issue is that not all centres in NZ have the trials open at their sites, forcing patients to try to travel to another region where a DHB may be offering a trial. Part of the problem is that drug trials require a lot of paperwork and oversight, and are therefore not all that well supported by some of the DHBs.

“While these issues are challenging for the health system, it is the patients whose interests we should be considering here, many of whom have run out of options and whose very survival is in the balance,” said Dr Romeril.

Multiple myeloma is a blood cancer of malignant plasma cells and is now the second commonest and second fastest growing blood cancer in the world.

Each year around 380 New Zealanders will develop this serious condition, and around 1800 are currently living with it.

Dr Romeril said that from 2011 New Zealand had been able to get access to Bortezomib, a new drug that improved the average survival from 3 to 4 years to around 6 to 7 years.

“New Zealand managed to achieve funded access to Bortezomib before Australia and we were leading them in terms of patient survival. But Australia has since made gains with improved access to a Thalidomide spin-off named Lenalidomide and have also been able to offer relapsed patients a compassionate programme for Daratumamab, which is proving very effective.

“So once again we are slipping behind Australia, and while it’s not surprising that some New Zealand patients have managed to move to Australia to get the drug, that’s not an option open to most of our patients.

battling myeloma and find the money to widen access to this and other more effective myeloma drugs, so that we can continue to build on the gains achieved over the last decade,” said Dr Romeril.

ENDS

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Joseph Cederwall Review: NZSO Plays Zappa

The first of the NZSO’s Shed Series concerts at the more informal and intimate space of Wellington's Shed 6 last Friday night featured music composed by, or with a connection to Frank Zappa. Zappa, a psychedelic rock legend, activist and popular culture figure and all round colourful character, was an excellent choice for the concert’s theme of innovation. More>>

Let The Games Begin: PM Sends Best Wishes To Athletes

Prime Minister Jacinda Ardern has sent her warm wishes to the New Zealand athletes preparing for the opening of the Commonwealth Games on Australia’s Gold Coast... More>>

ALSO:

Scoop Review of Books: Martin Edmonds' The Expatriates

This book is an extension of, and tribute to, the life’s work of James McNeish. Without sacrificing any degree of authorial independence, the result is gracefully written, handsomely produced, and likely to propagate many further works of its kind. More>>

Max Rashbrooke Review: The King's Singers and Voices New Zealand

To be good at one thing is impressive; to be so versatile across a range of genres is truly exceptional. More>>

Joe Cederwall Review: WOMAD 2018 - Harmony of Difference (part 1)

A friend described WOMAD as his “favourite white middle class celebration of diversity.” There is certainly an echo of truth to this as the crowd is still largely white and middle class, but this WOMAD for me represented that a better world is possible ... More>>

Harmony of Difference (part 2)

Top international world music artists seldom make it down to this neck of the woods, so for those of us into this sort of thing WOMAD is certainly a welcome addition to the cultural calendar. Now it is a case of waiting and looking forward to seeing what they manage to conjure up for next year. More>>

Howard Davis Review: A Bigger Splash - Te Papa Celebrates Twenty Years

Considering the available resources, this is a decidedly hit-and-miss affair, mainly due to some highly questionable curatorial decisions. In their overweening wish to "push boundaries," Charlotte Davy and Megan Tamati-Quennell have made a number of serious miscalculations by ignoring a basic rule - keep it simple. More>>

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland